7 Sep 2026
On World Duchenne Awareness Day 2026, we are pleased to share the launch of the Duchenne Care UK podcast series, supporting the goal of delivering consistent, high-quality care across the UK. The series is based on the Duchenne Care UK Patient and Family Guides, and...
8 May 2026
On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft...
7 May 2026
Today, Solid Biosciences announced that the first participant has been dosed in the Phase 3 Impact Duchenne clinical trial, a randomised, double-blind, placebo-controlled study evaluating SGT-003 for Duchenne. Clinical trial sites are currently active in Australia and...
30 Apr 2026
We are delighted to share that psychosocial guidelines for Duchenne muscular dystrophy have been published by Duchenne Care UK. We are proud to be a key funder of the psychosocial programme, which is part of a wider, multi‑year national effort by Duchenne Care UK to...
12 Mar 2026
Solid Biosciences has announced a positive clinical update on the SGT-003 gene therapy programme. This update includes interim safety and biomarker data from the ongoing Phase 1/2 Inspire Duchenne clinical trial. To date, 40 participants have been dosed with SGT-003...
9 Dec 2025
Scottish Medicines Consortium (SMC) has approved the treatment givinostat for use on the NHS in Scotland, for children aged 6+ who are still able to walk at the start of treatment. Givinostat (also known by its brand name Duvyzat) was approved for market authorisation...
10 Nov 2025
Solid Biosciences has released an update on its Inspire Duchenne clinical trial, which is investigating the safety, tolerability and efficacy of its gene therapy candidate SGT-003. The Phase 1/2, open-label study has now dosed 23 patients, and expects to have dosed 30...
15 Aug 2025
The UK’s National Institute for Health and Care Excellence (NICE) has announced it will seek further guidance on whether new treatment givinostat should be made routinely available on the NHS. NICE held its initial committee meeting to appraise the drug in July,...
31 Jul 2025
Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns. The request followed three deaths potentially related to the gene therapy products. The deaths appeared to...
2 Apr 2025
Pictured: DRF director of operations Sheli Rodney (second from right) with fellow members of the Psychosocial Working Group: disability and education specialist Dr Janet Hoskin, DMD Care UK manager Cathy Turner, Pathfinders Neuromuscular Alliance trustee Benjamin...